Case Study

Enrolling 720+ Participants Across Seven Phase 3 Flu Vaccine Sites

Tekton supported a global Phase 3 influenza vaccine trial across seven sites in three states, centralizing startup, regulatory, and recruitment support. Enrollment was open for two months and focused on generally healthy adults aged 50 and older, stratified into three age groups. Centralized startup and year-round recruitment preparation helped the sites move quickly during a competitive vaccine season.

  • Goal: 430 participants
  • Enrolled: More than 720 participants
  • 172% average enrollment across seven sites
  • Less than 12 hours on average from activation to first participant visit
  • 3-day average regulatory turnaround

Talk to Tekton

Pneumococcal Vaccine Research Study

About This Study

CLIENT
Leading global vaccine developer
TRIAL
Global Phase 3 influenza vaccine trial
PARTICIPANT POPULATION
Generally healthy adults aged 50 and older, stratified into three age groups
TEKTON COVERAGE
Seven sites

Partner With Tekton

Join leading Sponsors and CROs that trust Tekton's sites to support their most important clinical trials.

Complete the form on this page or email to discuss your protocol, target population, timelines, and site needs.

Submit Your Information